^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    07/05/2023
    Excerpt:
    Docetaxel Injection is a microtubule inhibitor indicated for: Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC...